Contract signed: Sanofi shares hardly change, Moderna shares strong: Sanofi produces Moderna vaccine for the USA | message
Shares in this article
The French company Sanofi announced that it will fill the bottles and complete the packaging of the Moderna vaccine at the Sanofi facility in Ridgefield.
A Sanofi spokesman said the finished doses of the Moderna vaccine will be supplied to the United States under an agreement that runs through April 2022. The agreement is the latest addition to production capacity to increase supply. It is also a new example of collaboration within the industry in an effort to rapidly increase global production of COVID-19 vaccines.
Moderna plans to deliver a total of 300 million doses of its COVID-19 vaccine for use in the United States by the end of July, which should help meet President Biden’s goal of vaccinating the majority of American adults by the summer.
Pfizer Inc with its partner Biontech SE and Johnson & Johnson are also supplying vaccine doses to achieve this goal. Moderna and Pfizer vaccines are given in two doses a few weeks apart, while J & J’s vaccine requires a single dose. Since Sanofi’s contribution is not due to start until September, the Moderna vaccine doses that Sanofi is contributing could be used to vaccinate children under the age of 18, if the vaccine is approved for them, or for booster shots if this is to maintain immunity are required in adults. It is also possible that Sanofi’s capacities will be used for Moderna’s modified COVID-19 vaccines, which target newer variants of the coronavirus. Moderna is testing such a vaccine in a clinical trial and has said it may be able to file for approval for the vaccine in the third quarter.
The Sanofi share gained only 0.05 percent to 85.38 euros at EURONEXT in Paris by the end of trading. For Moderna shares, the NASDAQ is meanwhile on Monday at times by 3.02 percent up to 178.87 US dollars.
DJG / DJN / jhe / sha
NEW YORK (Dow Jones)
More news about Merck Co.
Image Sources: 360b / Shutterstock.com